News

Glenmark Pharmaceuticals Announces Acetylcysteine Injection Launch

Glenmark Pharmaceuticals Announces Acetylcysteine Injection Launch

Glenmark Pharmaceuticals Inc. Launches New Injectable Product

Glenmark Pharmaceuticals Inc., a key player in the global pharmaceutical arena, has made an impactful announcement regarding the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This innovative product is set to bolster Glenmark's extensive injectable portfolio and enhance its offerings in the North American market.

Details About Acetylcysteine Injection

The newly launched Acetylcysteine Injection is expected to deliver therapeutic benefits comparable to the established Acetadote® Injection, a product previously relied upon for its safety and effectiveness. Glenmark successfully acquired the Abbreviated New Drug Application (ANDA) for this drug from Aspen Pharma, bringing an essential treatment option to healthcare providers and patients alike.

Market Insights

According to the latest IQVIA™ sales data, the market for Acetadote® Injection saw impressive annual sales of approximately $15.2 million, indicating a robust demand for acetylcysteine products. This underscores the importance of Glenmark's entry into this segment, as it aims to capture a share of this lucrative market.

Glenmark's Strategic Vision

Marc Kikuchi, President & Business Head of North America, expressed enthusiasm about the acquisition and launch. He stated, "We are excited to announce the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This is a great addition to our injectable portfolio in the U.S. market as we continue to drive growth for the hospital segment." This statement emphasizes Glenmark's commitment to advancing healthcare solutions.

Company Overview

Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is renowned for its extensive research-focused approach in the pharmaceutical industry. The company operates across diverse segments including branded medications, generics, and over-the-counter (OTC) products. Glenmark's therapeutic concentrations cover vital areas such as respiratory, dermatology, and oncology, reflecting its strategic market positioning.

With 11 state-of-the-art manufacturing facilities across four continents and operations in more than 80 countries, Glenmark stands amongst the top biopharmaceutical companies as ranked by various industry authorities. Notably, in 2023, Glenmark was recognized in the Scrip 100 listing of top pharmaceutical firms based on sales achievements.

Commitment to Sustainability

The company is also dedicated to sustainability. Glenmark's Greenhouse Gas (GHG) emission reduction goals gained approval in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to attain such recognition. Glenmark's initiatives over the last decade have positively impacted over 3.3 million lives through comprehensive corporate social responsibility (CSR) efforts.

Frequently Asked Questions

What is Acetylcysteine Injection used for?

Acetylcysteine Injection is used primarily to treat acetaminophen overdose and to support respiratory conditions by loosening mucus in the airways.

What are the benefits of Glenmark's new Acetylcysteine Injection?

The new injection offers a safe and effective treatment similar to existing products and enhances Glenmark's presence in the injectable market.

How does Glenmark support sustainability?

Glenmark has implemented goals to reduce greenhouse gas emissions and has been recognized for its commitment to sustainability by the Science Based Target initiative.

In which therapeutic areas does Glenmark specialize?

Glenmark specializes in multiple therapeutic areas including respiratory medicine, dermatology, and oncology, focusing on developing innovative treatments.

Where can I learn more about Glenmark Pharmaceuticals?

More information can be found on Glenmark's official website and their social media platforms.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 362

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 39

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 583

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Daily Insights on WisdomTree Fund Prices and Holdings Update

Updated Category News Views 284

WisdomTree Fund Prices Overview In today’s ever-evolving financial landscape, understanding fund prices is crucial for investors. WisdomTree Issuer plc offers a range of funds that are pivotal to the investment strategy of many. With the latest updates from the fund market, let's delve into the details of some notable WisdomTree funds available for investment. Key...

Continue Reading
Impact of Drug Tariffs on American Patients and Insurers

Updated Category News Views 290

Understanding the Proposed Drug Tariffs Introduced by the Administration Recent discussions have centered around proposed 100% tariffs on foreign pharmaceuticals, primarily advocated by the administration. Economists warn that these tariffs will place a heavy financial burden on American patients and insurers rather than the foreign drug manufacturers. Economic Insights...

Continue Reading
AvidXchange Q2 2025 Results: Growth Amid Strategic Changes

Updated Category News Views 445

AvidXchange Reports Strong Financial Growth in Q2 2025 AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leader in accounts payable (AP) automation software, has published its financial results for the second quarter ended June 30, 2025. The company showcases growth despite various strategic changes, particularly surrounding its pending acquisition. Financial Highlights for Q2...

Continue Reading
Talkiatry Ranks #6 in Digital Health Innovation for 2024

Updated Category News Views 552

Talkiatry Achieves Recognition in Digital Health Talkiatry has been honored as the sixth most innovative digital health startup for 2024. This accolade is a testament to the significant impact the organization is making in the field of behavioral health care. Significance of the CB Insights Ranking Chosen by CB Insights, Talkiatry's ranking reflects a combination of...

Continue Reading
Innovative Partnership Enhances SBA Loan Accessibility for Businesses

Updated Category News Views 267

BizBuySell and LoanBud Collaboration Enhances Financing for Businesses BizBuySell, the leading business-for-sale marketplace, has teamed up with LoanBud, a fintech innovator specializing in SBA financing. This collaboration significantly transforms the experience of buying or selling small businesses by increasing transparency and clarity in the financing process from the...

Continue Reading